December 10, 2018
Chugai Pharmaceutical said on December 7 that it has filed an additional indication for its anti-PD-L1 antibody Tecentriq (atezolizumab) in Japan for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The filing is based on data from the...read more